A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants

Launched by ELI LILLY AND COMPANY · Jun 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medicine called olomorasib to understand how it moves through the body—specifically, how much of the drug gets into the bloodstream and how long it takes for the body to clear it out. The study involves healthy adults taking olomorasib capsules by mouth. It will last about seven weeks and includes 10 consecutive overnight stays at the research center so the team can carefully monitor participants.

To take part, you need to be a healthy adult with a body mass index (BMI) between 18 and 30, and not able to have children (for example, men or women who are not of childbearing potential). The study is not open to women who are breastfeeding or could become pregnant, or anyone with a history of allergies to drugs or certain foods. Participants should also avoid most medications before joining, except occasional low doses of acetaminophen (Tylenol). If you qualify, you can expect close monitoring while taking the medication and during your stays at the center to help researchers learn how olomorasib behaves in the body.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease
• • Body mass index (BMI): 18.0 to 30.0 kilograms per square meter (kg/m²), inclusive
• • Participants assigned male at birth (AMAB) or assigned female at birth (AFAB) who are individuals not of childbearing potential (INOCBP).
• Exclusion Criteria:
• • Females who are lactating or of childbearing potential
• • Clinically significant history of any drug sensitivity, drug allergy, or food allergy
• • Have used or plan to use medication within 14 days or 5 half-lives, whichever is longest, prior to admission, with the exception occasional acetaminophen at doses less than or equal to 2 g/day.